Hims & Hers Surges Ahead of Earnings as Omnicell Lags in Healthcare Tech Shakeout
Hims & Hers Health shares jumped 8.9% Monday morning, extending a 48.3% weekly gain ahead of its May 11 earnings report. The FDA will meet in July to consider rules on compounding peptides, a market Hims entered last year. Hims ended 2025 with 2.511 million subscribers and $617.8 million in fourth-quarter revenue, up 28%. Omnicell reported $314 million in fourth-quarter revenue and a $2 million net loss.